Trial Profile

A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpha 1-antitrypsin (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection; Respiratory distress syndrome
Focus Therapeutic Use

Most Recent Events

26 Jul 2022 Primary endpoint has been met (Change in plasma IL-6 concentration at day 7) , according to Results presented at the 118th International Conference of the American Thoracic Society
15 Apr 2021 Status changed from recruiting to completed.
26 Oct 2020 Planned End Date changed from 24 Aug 2020 to 24 Apr 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com